At Novartis, our purpose is to reimagine medicine to improve and extend people’s lives. To achieve this, we engage in dialogue with policymakers and other stakeholders on relevant policy topics including supporting innovation in the life sciences and expanding access to medicines.
We believe that constructive engagement based on evidence-based data and scientific insights help to inform public policy and promote understanding among our stakeholders. In representing the perspective of Novartis to external stakeholders, we aim to be a trusted partner that works together with governments, regulatory bodies and others to create positive impact for patients, healthcare systems and society.
Our approach – partner of choice
Innovation is core to what we do at Novartis. For innovation to thrive, it should be underpinned by a robust and progressive legislative foundation. To this end, we aim to provide policymakers with key insights that can help facilitate vital decisions for today and tomorrow.
The Novartis Public Affairs function assesses political, legislative, and regulatory decisions that have a potential impact on patients and on our industry across the globe. We participate in policy discussions regarding the future of healthcare with partners through various stakeholder dialogues and industry platforms.
Our focus is on creating solutions together with our partners that help communities and society tackle the burden of disease. Engaging with trade associations also facilitates a collaborative approach to highlighting and solving issues that affect patients.
In all of our activities, we encourage associates to take personal accountability for their decisions. We adhere to high standards of transparency and ethical behavior.
Our principles for responsible lobbying
At Novartis, we are guided by three principles when conducting lobbying activities:
- Principle 1: Transparency, honesty and integrity are the core values reflected in how Novartis conducts lobbying activities.
- Principle 2: All lobbying activities should inform policy-making in favor of improving and extending people’s lives through innovative science and technology, delivering breakthrough treatments to as many people as possible and sustaining a rewarding business environment.
- Principle 3: Novartis associates must not attempt to improperly influence any decision by inducing lobbied stakeholders to act in violation of their lawful duties.